Glatiramer acetate and interferon beta-1a for intramuscular administration: A study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts

Journal of Medical Economics

Volumn 13, Issue 3, 2010, Pages 464-471

  Castelli Haley, Jane ^a   Oleen Burkey, Merrikay A ^a   Lage, Maureen J ^b   Johnson, Kenneth ^c  

^a Teva Neuroscience Inc   (United States)

^b HealthMetrics Outcomes Research LLC   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

Costs; Glatiramer acetate; Interferon beta 1a; Multiple sclerosis; Relapse

Indexed keywords

BETA1 INTERFERON; BETA1A INTERFERON; GLATIRAMER;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOMES RESEARCH; RELAPSE;

ADJUVANTS, IMMUNOLOGIC; ADULT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; INSURANCE CLAIM REVIEW; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS; MULTIVARIATE ANALYSIS; PEPTIDES; RECURRENCE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77956662173     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696998.2010.496650     Document Type: Article

References (43)

1. Frohman EM, Frohman TC, Zee DS, et al. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol 2005;4:111-121
2. Frohman EM. Multiple sclerosis. Med Clin North Am 2003;87:867-897, viii-ix
3. Multiple Sclerosis International Federation. About MS: what is MS? Accessed October 6, 2008. http://www.msif.org/en/about-ms/what-is-ms.html
4. National Multiple Sclerosis Society. About MS: who gets MS? Accessed October 6, 2008. Available at http://www.nationalmssociety.org/about-multiple- sclerosis/who-gets-ms/index.aspx
5. Noonan CW, Kathman SJ, White MC. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology 2002;58:136-138
6. Richards RG, Sampson FC, Beard SM, et al. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 2002;6:1-73
7. Multiple Sclerosis International Federation. About MS: introduction. Accessed October 6, 2008. http://www.msif.org/en/about-ms/index.html
8. Parkin D, Jacoby A, McNamee P, et al. Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry 2000;68:144-149
9. Murphy N, Confavreux C, Haas J, et al. Quality of life in multiple sclerosis in France, Germany and the United Kingdom. Cost of Multiple Sclerosis Study Group. J Neurol Neurosurg Psychiatry 1998;65:460-466
10. Multiple Sclerosis International Federation. About MS: recognised treatment for MS. Accessed October 6, 2008. http://www.msif.org/en/about-ms/ recognised-treat.html
11. Tullman MJ, Lublin FD, Miller AE. Immunotherapy of multiple sclerosis-current practice and future directions. J Rehabil Res Dev 2002;39:273-286
12. Pohlman CH, Uitdehaag BM. Drug treatment of multiple sclerosis. BMJ 2000; 321:490-494
13. Calabresi P. Investigating glatiramer acetate for relapsing-remitting multiple sclerosis at the double dose-is more better? Nat Clin Pract Neurol 2007;3:540-541
14. Ford CC, Johnson KP, Lisak RP, et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler 2006;12:309-320
15. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998;50:701-708
16. Jacobs LD, Cookfair DL, RudickRA, et al.Intramuscular interferon beta-1afor disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294
17. Sela M, Teitelbaum D. Glatiramer acetate in the treatment of multiple sclerosis. Expert Opin Pharmacother 2001;2:1149-1165
18. Davis WM. Multiple sclerosis: continuing mysteries and current management. Drug Topics 2000;144:93-102
19. Vallittu AM, Peltoniemi J, Elovaara I, et al. The efficacy of glatiramer acetate in beta-interferon-intolerant MS patients. Acta Neurol Scand 2005;112: 234-237
20. Prosser LA, Kuntz KM, Bar-Or A, et al. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health 2004;7:554-568
21. Chilcott J, McCabe C, Tappenden P, et al. Modeling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. BMJ 2003;326:522-525
22. Goldberg LD, Edwards NC, Fincher C, et al. Comparing the cost-effectiveness of disease-modifying drugs for the first line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm 2009;15:543-555
23. Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness of 4 immuno-modulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm 2007;13: 245-261
24. Phillips CJ. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment. Curr Opin CNS Drugs 2004;18:561-574
25. Peterson AM, Nau DP, Cramer JA, et al.A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12
26. Morrow T. The costs and consequences of multiple sclerosis relapses: a managed care perspective. J Neurol Sci 2007;256:S39-44
27. Ollendorf D, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm 2002; 8:469-476
28. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-808
29. Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008;71:129-135
30. National Multiple Sclerosis Society. About MS: epidemiology of MS. Accessed October 8, 2008. Available at http://www.nationalmssociety.org/about- multiple-sclerosis/who-gets-ms/epidemiology-of-ms/index.aspx
31. Marrie R, Horwitz R, Cutter G, et al. Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler 2008;14:1091-1098
32. Miller A. Paroxysmal disorders. In Burkes JS, Johnson KP, eds. Multiple Sclerosis: Diagnosis, Medical Management, and Rehabilitation. New York: Demos Medical Publishing, 382
33. Pollmann W, Feneberg W. Current management of pain associated with multiple sclerosis. CNS Drugs 2008;22:291-324
34. Patten SB, Francis G, Metz LM, et al. The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Mult Scler 2005;11:175-181 (Pubitemid 40403256)
35. Biogen, Inc. Medication guide: Avonex -interferon beta-1a. Published January 31, 2003. Available at http://www.fda.gov/cder/foi/label/2003/ ifnbbio013103mg.pdf
36. Haas J, Firzlaff M. Twenty-four-month comparison of immunomodulatory treatments -a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone®). Eur J Neurol 2005;12:425-431
37. Carra A, Onaha P, Sinay V, et al. A retrospective, observational study comparing the four available immunomodulatory treatments for relapsing-remitting multiple sclerosis. Eur J Neurol 2003;10:671-676
38. Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 2000;6: 255-266
39. Clanet M, Kappos L, Hartung HP, et al. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose Comparison Study. Mult Scler 2004;10:139-144
40. Prescott JD, Factor S, Pill M, et al. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007;13:44-52
41. Kobelt G, Berg J, Atherley D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the USA. Neurology 2006;66:1696-1702 (Pubitemid 43964625)
42. Whetten-Goldenstein K, Sloan FA, Goldenstein LB, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998;4:419-425
43. i3. Data assets: better data matters. Accessed October 8, 2008. http://www.i3global.com/DataAssets/